Filing Details
- Accession Number:
- 0001012975-17-000656
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-08-24 17:48:59
- Reporting Period:
- 2017-08-22
- Accepted Time:
- 2017-08-24 16:48:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1326190 | Altimmune Inc. | ALT | Pharmaceutical Preparations (2834) | 202726770 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1428764 | David Drutz | C/O Altimmune, Inc. 19 Firstfield Road, Suite 200 Gaithersburg MD 20878 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.0001 | Acquisiton | 2017-08-22 | 5,000 | $2.15 | 25,777 | No | 4 | P | Direct | |
| Common Stock, Par Value $0.0001 | Acquisiton | 2017-08-23 | 5,000 | $2.27 | 30,777 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | P | Direct |
Footnotes
- The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.08 to $2.16 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price.
- The price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.23 to $2.28 per share. The Reporting Person undertakes to provide, upon request by the Issuer, any security holder of the Issuer, or the SEC staff, full information regarding the number of shares purchased at each separate price.
Billionaire Hedge Funds
